Evidence map›Paper›PMID 33688021›Full record

ArticleJournal for immunotherapy of cancer2021

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.

Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra and 3 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Upregulated PPP1R14B is connected to cancer progression and immune infiltration in kidney renal clear cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alexander Chehrazi-Raffle *Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Luis Meza *Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Marice Alcantara *Department of Immuno-Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Nazli DizmanDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-3907-8513
Paulo BergerotDepartment of Medical Oncology, Cettro Cancer Center, Brasilia, Brazil.
Nicholas SalgiaJacobs School of Medicine and Biomedical Sciences, Buffalo, New York, Brazil.
JoAnn HsuDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Nora RuelDepartment of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Sabrina SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Jasnoor MalhotraDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Ewa KarczewskaDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Sumanta PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA spal@coh.org.ORCID 0000-0002-1712-0848
City of Hope · USJacobs Institute · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating cytokines and angiogenic factors have been associated with clinical outcomes in patients with metastatic renal cell carcinoma (RCC) receiving systemic therapy. However, none have yet examined cytokine concentrations in parallel cohorts receiving either immunotherapy or targeted therapy.

methodsIn this prospective correlative study, we enrolled 56 patients who were planned for treatment with either a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) or immune checkpoint inhibitor (ICI). Eligibility requirements permitted any RCC histologic subtype, International Metastatic Renal Cell Carcinoma risk classification, and line of therapy. Immunologic profile was assessed at baseline and after 1 month on treatment using a Human Cytokine 30-plex protein assay (Invitrogen). Clinical benefit was defined as complete response, partial response, or stable disease ≥6 months per RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria.

resultsClinical benefit was similar between VEGF-TKI and ICI arms (65% vs 54%). Patients with clinical benefit from VEGF-TKIs had lower pretreatment levels of interleukin-6 (IL-6) (p=0.02), IL-1RA (p=0.03), and granulocyte colony-stimulating factor (CSF) (p=0.02). At 1 month, patients with clinical benefit from ICIs had higher levels of interferon-γ (IFN-γ) (p=0.04) and IL-12 (p=0.03). Among patients on VEGF-TKIs, those with clinical benefit had lower 1 month IL-13 (p=0.02) and granulocyte macrophage CSF (p=0.01) as well as higher 1 month VEGF (p=0.04) compared with patients with no clinical benefit.

conclusionFor patients receiving VEGF-TKI or ICI therapy, distinct plasma cytokines were associated with clinical benefit. Our findings support additional investigation into plasma cytokines as biomarkers in metastatic RCC.

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsCarcinoma, Renal CellCytokinesFemaleHumansImmune Checkpoint InhibitorsKidney NeoplasmsMaleMiddle AgedMolecular Targeted TherapyPredictive Value of TestsProspective StudiesProtein Kinase InhibitorsAngiogenesis InhibitorsCytokinesImmune Checkpoint InhibitorsProtein Kinase Inhibitorsbiomarkerscytokinesimmunotherapytumor

Identifiers

PMID33688021
PMCPMC7944971
OpenAlexW3134715671

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.